SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:f5d1fc31-cd55-4ab0-9c25-297750abb9a2"
 

Search: onr:"swepub:oai:lup.lub.lu.se:f5d1fc31-cd55-4ab0-9c25-297750abb9a2" > Impact of different...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Salvagno, G. L. (author)

Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation

  • Article/chapterEnglish2007

Publisher, publication year, extent ...

  • Wiley,2007

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:f5d1fc31-cd55-4ab0-9c25-297750abb9a2
  • https://lup.lub.lu.se/record/675200URI
  • https://doi.org/10.1111/j.1365-2516.2006.01400.xDOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • In order to describe the haemostatic role of a variation in inhibitor reactivity with different factor VIII (FVIII) concentrates, we have compared inhibitor titres against a panel of FVIII concentrates and correlated titre with the capacity to inhibit thrombin generation. Three plasma-derived concentrates were tested in vitro in mixing experiments with inhibitor plasmas from 11 patients with severe haemophilia A: Fanhdi, which contains von Willebrand factor (VWF) with a final ratio of approximately 1:1 (VWF IU per IU FVIII:Q; Haemate-P with a ratio of 2.5:1 and Hemofil-M containing only trace amounts of VWF. In addition, the recombinant FVIII concentrate Kogenate Bayer containing no VWF was included. Inhibitor titres and the capacity to generate thrombin were measured. A statistically significant difference in measured titres was found with the highest titres recorded against Hemofil-M. The inhibitor titres needed to inhibit 50% maximum thrombin generation were the lowest for Kogenate Bayer and the highest and similar for Fanhdi and Haemate-P with intermediate titres needed for inhibition of Hemofil-M. In this study, the thrombin generation assay provides additional indications for the role of VWF in the treatment of patients with inhibitors. The VWF-containing concentrates Fanhdi and Haemate-P, added to FVIII-deficient plasma with the presence of inhibitor, generate more thrombin than do the purified concentrates Hemofil-M and Kogenate Bayer.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Astermark, JanLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-jas (author)
  • Ekman, MajLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-mek (author)
  • Franchini, M. (author)
  • Midi, G. C. (author)
  • Lippi, G. (author)
  • Poli, G. (author)
  • Berntorp, ErikLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-ebe (author)
  • Klinisk koagulationsmedicin, MalmöForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Haemophilia: Wiley13:1, s. 51-561351-82161365-2516

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view